MEASUREMENT OF PLATELET ACTIVATION MARKERS CD62P AND CD63 TO DETERMINE THE EFFICIENCY OF DUAL THERAPY WITH ASPIRIN AND CLOPIDOGREL: A PRELIMINARY STUDY
DOI:
https://doi.org/10.55374/jseamed.v8.207Keywords:
antiplatelet monitoring, drug effectiveness, dual antiplatelet therapy, flow cytometry, platelet aggregation testAbstract
Background: A dual antiplatelet therapy with aspirin and clopidogrel is advised to prevent stent thrombosis. However, the most appropriate assay for evaluating the antiplatelet effects remains undefined.
Objective: This study aimed to assess the efficacy of measuring platelet surface activation markers, CD62P and CD63, using flow cytometry to determine the effectiveness of dual antiplatelet therapy.
Methods: Thirty patients who received aspirin plus clopidogrel before cerebral artery stent implantation and thirty unrelated healthy controls were enrolled. The expression of CD62P and CD63 was measured using flow cytometry. The diagnostic performances were evaluated and compared with the conventional light-transmitted aggregometry (LTA) using 5.0 and 20.0 µM of adenosine di-phosphate (ADP).
Results: The expression ratios of both markers were significantly lower in the patients receiving dual antiplatelet therapy than controls (p < 0.001). The area under the receiver operating characteristic (ROC) curve (AUC) of CD62P using flow cytometry and the LTA using 5.0 and 20.0 µM of ADP were comparable (0.97 vs. 0.95 and 0.97 vs. 0.96, respectively), whereas those of CD63 was lower than the LTA (0.88 vs. 0.96). The sensitivity of CD62P and CD63 were 71.4% and 60.0%, and the specificity of CD62P and CD63 were 100.0% and 96.7%, respectively.
Conclusion: Flow cytometry measurements of CD62P could be utilized to identify the efficacy of dual antiplatelet therapy. Additional studies are suggested to support this issue and its effects on clinical outcomes.
Metrics
References
Thachil J. Antiplatelet therapy - a summary for the general physicians. Clin Med (Lond). 2016; 16: 152-60. https://doi.org/10.7861/clinmedicine.16-2-152 DOI: https://doi.org/10.7861/clinmedicine.16-2-152
Grines CL, Bonow RO, Casey DE Jr., Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813-8. https://doi.org/10.1161/CIRCULATIONAHA.106.180944 DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.180944
Jain R, Sood J. Antiplatelet therapy in patients with coronary artery stents for noncardiac surgery: Role of thromboelastography. J Anaesthesiol Clin Pharmacol 2011; 27: 537-40. https://doi.org/10.4103/0970-9185.86603 DOI: https://doi.org/10.4103/0970-9185.86603
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106. https://doi.org/10.1136/bmj.308.6921.81 DOI: https://doi.org/10.1136/bmj.308.6921.81
CURRENT-OASIS 7 Investigators; Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-42. https://doi.org/10.1056/NEJMoa0909475 DOI: https://doi.org/10.1056/NEJMoa0909475
Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-82. https://doi.org/10.1056/NEJMoa1001266 DOI: https://doi.org/10.1056/NEJMoa1001266
Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF, et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One 2012; 7: e31642. https://doi.org/10.1371/journal.pone.0031642 DOI: https://doi.org/10.1371/journal.pone.0031642
Caprie Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39. https://doi.org/10.1016/S0140-6736(96)09457-3 DOI: https://doi.org/10.1016/S0140-6736(96)09457-3
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. https://doi.org/10.1056/NEJMoa010746 DOI: https://doi.org/10.1056/NEJMoa010746
Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617. https://doi.org/10.1161/01.STR.0000199147.30016.74 DOI: https://doi.org/10.1161/01.STR.0000199147.30016.74
Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13. https://doi.org/10.1161/01.CIR.0000072771.11429.83 DOI: https://doi.org/10.1161/01.CIR.0000072771.11429.83
ACTIVE Investigators; Connolly S J, Pogue J, Hart R G, Hohnloser S H, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78. https://doi.org/10.1056/NEJMoa0901301 DOI: https://doi.org/10.1056/NEJMoa0901301
Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation 2010; 122: 2680-7. https://doi.org/10.1161/CIRCULATIONAHA.110.978007 DOI: https://doi.org/10.1161/CIRCULATIONAHA.110.978007
Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2012; 9: 441-6. https://doi.org/10.7150/ijms.4549 DOI: https://doi.org/10.7150/ijms.4549
Diener HC, Weber R. Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke. Stroke 2013; 44: 861-3. https://doi.org/10.1161/STROKEAHA.112.680751 DOI: https://doi.org/10.1161/STROKEAHA.112.680751
Krishnan K, Nguyen TN, Appleton JP, Law ZK, Caulfied M, Cabrera CP, et al. Antiplatelet resistance: A review of concepts, mechanisms, and implications for management in acute ischemic stroke and transient ischemic attack. Stroke Vasc Interv Neurol 2023; 3: e000576. https://doi.org/10.1161/SVIN.122.000576 DOI: https://doi.org/10.1161/SVIN.122.000576
Guirgis M, Thompson P, Jansen S. Review of aspirin and clopidogrel resistance in peripheral arterial disease. J Vasc Surg 2017; 66: 1576-86. https://doi.org/10.1016/j.jvs.2017.07.065 DOI: https://doi.org/10.1016/j.jvs.2017.07.065
Karunawan NH, Pinzon RT. Prevalence of aspirin and clopidogrel resistance in patients with recurrent ischaemic cerebrovascular disease. Eur Cardiol 2021; 16: e72. https://doi.org/10.15420/ecr.2021.16.PO16 DOI: https://doi.org/10.15420/ecr.2021.16.PO16
Marginean A, Banescu C, Scridon A, Dobreanu M. Antiplatelet therapy resistance - concept, mechanisms and platelet function tests in intensive care facilities. J Crit Care Med (Targu Mures). 2016; 2: 6-15. https://doi.org/10.1515/jccm-2015-0021 DOI: https://doi.org/10.1515/jccm-2015-0021
Lordkipanidze M. Platelet function tests. Semin Thromb Hemost 2016; 42: 258-67. https://doi.org/10.1055/s-0035-1564834 DOI: https://doi.org/10.1055/s-0035-1564834
Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-8. https://doi.org/10.1093/eurheartj/ehm226 DOI: https://doi.org/10.1093/eurheartj/ehm226
Grau A J, Reiners S, Lichy C, Buggle F, A. R. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003; 34: 849-54. https://doi.org/10.1161/01.STR.0000064326.65899.AC DOI: https://doi.org/10.1161/01.STR.0000064326.65899.AC
Lu BC, Shi XJ, Liang L, Dong N, Liu ZZ. Platelet surface CD62p and serum vitamin D levels are associated with clopidogrel resistance in Chinese patients with ischemic stroke. J Stroke Cerebrovasc Dis 2019; 28: 1323-8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.01.031 DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.01.031
Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009; 35: 158-67. https://doi.org/10.1055/s-0029-1220324 DOI: https://doi.org/10.1055/s-0029-1220324
Carubbi C, Masselli E, Gesi M, Galli D, Mirandola P, Vitale M, et al. Cytofluorimetric platelet analysis. Semin Thromb Hemost 2014; 40: 88-98. https://doi.org/10.1055/s-0033-1363472 DOI: https://doi.org/10.1055/s-0033-1363472
Khan H, Kanny O, Syed MH, Qadura M. Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy. Int J Mol Sci 2022; 23: 11317. https://doi.org/10.3390/ijms231911317 DOI: https://doi.org/10.3390/ijms231911317
Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-62. https://doi.org/10.1001/jama.2010.181 DOI: https://doi.org/10.1001/jama.2010.181
Nagy B Jr, Debreceni IB, Kappelmayer J. Flow cytometric investigation of classical and alternative platelet activation markers. EJIFCC 2013; 23: 124-34.
Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007; 49: 1957-64. https://doi.org/10.1016/j.jacc.2007.02.038 DOI: https://doi.org/10.1016/j.jacc.2007.02.038
Cha JK, Jo WS, Shin HC, Bae HR, Ho JM, Kim JW. Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke. Platelets 2004; 15: 3-7. https://doi.org/10.1080/09537100310001644024 DOI: https://doi.org/10.1080/09537100310001644024
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Southeast Asian Medical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal of Southeast Asian Medical Research will hold the copyright to all published articles. The publisher's production department handles copyright forms once a manuscript is accepted and scheduled for publication.
